{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cleveland&page=32&state=Ohio",
    "query": {
      "state": "Ohio",
      "city": "Cleveland",
      "page": 32
    },
    "page_size": 10
  },
  "pagination": {
    "page": 32,
    "page_size": 10,
    "total_count": 11335,
    "total_pages": 1134,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cleveland&page=33&state=Ohio&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cleveland&page=31&state=Ohio&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T15:41:51.806Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07005128",
      "title": "A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Small-cell Lung Cancer",
        "Extensive Stage Small-cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Tarlatamab",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 350,
      "start_date": "2025-08-18",
      "completion_date": "2029-08-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-11-07T15:41:51.806Z",
      "location_count": 50,
      "location_summary": "Casa Grande, Arizona • Goodyear, Arizona • Hot Springs, Arkansas + 45 more",
      "locations": [
        {
          "city": "Casa Grande",
          "state": "Arizona"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07005128"
    },
    {
      "nct_id": "NCT00142792",
      "title": "Functional Electrical Stimulation (FES) for Upper Extremity Recovery in Stroke",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stroke, Acute",
        "Stroke",
        "Hemiparesis"
      ],
      "interventions": [
        {
          "name": "NMES device with EMG-triggered and Cyclic capabilities",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "MetroHealth Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "21 Years to 89 Years"
      },
      "enrollment_count": 122,
      "start_date": "2005-12",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2018-03-29",
      "last_synced_at": "2026-11-07T15:41:51.806Z",
      "location_count": 3,
      "location_summary": "Akron, Ohio • Cincinnati, Ohio • Cleveland, Ohio",
      "locations": [
        {
          "city": "Akron",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00142792"
    },
    {
      "nct_id": "NCT02275936",
      "title": "Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "N91115",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nivalis Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 51,
      "start_date": "2015-02",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2016-11-07",
      "last_synced_at": "2026-11-07T15:41:51.806Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02275936"
    },
    {
      "nct_id": "NCT01240902",
      "title": "Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Severe Aortic Stenosis"
      ],
      "interventions": [
        {
          "name": "Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)",
          "type": "DEVICE"
        },
        {
          "name": "Surgical Aortic Valve Replacement (SAVR)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Medtronic Cardiovascular",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1453,
      "start_date": "2010-12-10",
      "completion_date": "2019-05-15",
      "has_results": true,
      "last_update_posted_date": "2022-10-25",
      "last_synced_at": "2026-11-07T15:41:51.806Z",
      "location_count": 45,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Mountain View, California + 35 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01240902"
    },
    {
      "nct_id": "NCT02987972",
      "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pneumococcal Infections"
      ],
      "interventions": [
        {
          "name": "V114 Lot 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "V114 Lot 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 13™",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "12 Weeks",
        "sex": "ALL",
        "summary": "6 Weeks to 12 Weeks"
      },
      "enrollment_count": 1051,
      "start_date": "2017-03-21",
      "completion_date": "2018-10-04",
      "has_results": true,
      "last_update_posted_date": "2019-10-23",
      "last_synced_at": "2026-11-07T15:41:51.806Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Jonesboro, Arkansas + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Palmdale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02987972"
    },
    {
      "nct_id": "NCT06971939",
      "title": "Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Macular Telangiectasia Type 2 (MacTel)"
      ],
      "interventions": [
        {
          "name": "NT-501/revakinagene taroretcel-lwey",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Neurotech Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 234,
      "start_date": "2025-11-21",
      "completion_date": "2032-01-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-11-07T15:41:51.806Z",
      "location_count": 23,
      "location_summary": "La Jolla, California • Los Angeles, California • Palo Alto, California + 19 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06971939"
    },
    {
      "nct_id": "NCT07679919",
      "title": "BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Hodgkin Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Hairy Cell Leukemia",
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "LMY-922",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Luminary Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 27,
      "start_date": "2026-09",
      "completion_date": "2029-04",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-11-07T15:41:51.806Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07679919"
    },
    {
      "nct_id": "NCT03643965",
      "title": "Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary IgA Nephropathy"
      ],
      "interventions": [
        {
          "name": "Nefecon",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calliditas Therapeutics AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 365,
      "start_date": "2018-09-05",
      "completion_date": "2023-07-10",
      "has_results": true,
      "last_update_posted_date": "2024-12-03",
      "last_synced_at": "2026-11-07T15:41:51.806Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03643965"
    },
    {
      "nct_id": "NCT03732807",
      "title": "PF-06651600 for the Treatment of Alopecia Areata",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Alopecia Areata"
      ],
      "interventions": [
        {
          "name": "PF-06651600 Induction Dose",
          "type": "DRUG"
        },
        {
          "name": "PF-06651600 Maintenance Dose #1",
          "type": "DRUG"
        },
        {
          "name": "PF-06651600 Maintenance Dose #2",
          "type": "DRUG"
        },
        {
          "name": "PF-06651600 Maintenance Dose #3",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 718,
      "start_date": "2018-12-03",
      "completion_date": "2021-06-24",
      "has_results": true,
      "last_update_posted_date": "2022-02-24",
      "last_synced_at": "2026-11-07T15:41:51.806Z",
      "location_count": 46,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • Irvine, California + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03732807"
    },
    {
      "nct_id": "NCT00135811",
      "title": "Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glomerulosclerosis, Focal"
      ],
      "interventions": [
        {
          "name": "Cyclosporin",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil and Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "2 Years to 40 Years"
      },
      "enrollment_count": 192,
      "start_date": "2004-11",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-11-07T15:41:51.806Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00135811"
    }
  ]
}